Back to User profile » Dr Kristian Thorlund
Papers published by Dr Kristian Thorlund:
Synthetic and External Controls in Clinical Trials – A Primer for Researchers
Thorlund K, Dron L, Park JJH, Mills EJ
Clinical Epidemiology 2020, 12:457-467
Published Date: 8 May 2020
Critical concepts in adaptive clinical trials
Park JJH, Thorlund K, Mills EJ
Clinical Epidemiology 2018, 10:343-351
Published Date: 23 March 2018
Nonergot dopamine-receptor agonists for treating Parkinson's disease – a network meta-analysis
Thorlund K, Wu P, Druyts E, Eapen S, Mills EJ
Neuropsychiatric Disease and Treatment 2014, 10:767-776
Published Date: 7 May 2014
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis [Corrigendum]
Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ
Biologics: Targets and Therapy 2014, 8:57-58
Published Date: 7 February 2014
Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection
Druyts E, Thorlund K, Humphreys S, Lion M, Cooper CL, Mills EJ
Clinical Epidemiology 2013, 5:173-183
Published Date: 20 June 2013
Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis
Thorlund K, Druyts E, Aviña-Zubieta JA, Mills EJ
Biologics: Targets and Therapy 2012, 6:417-427
Published Date: 3 December 2012
Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
Thorlund K, Druyts E, El Khoury AC, Mills EJ
ClinicoEconomics and Outcomes Research 2012, 4:349-359
Published Date: 16 November 2012
Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation study
Mills E, Thorlund K
Clinical Epidemiology 2012, 4:75-85
Published Date: 16 April 2012
Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, Mills EJ
Therapeutics and Clinical Risk Management 2012, 8:105-130
Published Date: 9 March 2012